Navigation Links
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Date:11/20/2008

till over 40,000 deaths per year due to the disease in the Unites States alone.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
4. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
9. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
10. Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... DALLAS April 22, 2014 Researchers at UT ... people suffering from depression . , A ... major mechanism by which ghrelin (a hormone with natural ... identified a potentially powerful new treatment for depression in ... , The study, published online in April,s ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... 22 April 2014. The latest scientific advances and emerging ... Failure 2014, the main annual meeting of the Heart ... (ESC). Journalists will also hear breaking news on acute ... Heart Failure, which is part of the main congress. ... Athens, Greece, at the Megaron Athens International Conference Centre ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... 11, 2008 The American Cancer Society announced today ... for Exemplary Leadership in Tobacco Control. The awards are ... L. Terry, M.D., who led the landmark 1964 Surgeon ... and other illnesses. Dr. Terry,s courageous and groundbreaking work ...
... Deanna Vankessel, author of the recently published G lobal Markets ... to offer extensive expertise on the recent FDA premarket approval recommendation of ... , , MRG,s Deanna Vankessel is available ... , How ...
... Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), ... neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These ... breast cancer positive for the ErbB-2 receptor (also known as HER-2 ...
... Health Company (NYSE Alternext: FHC) has announced that the U.S. ... Committee has unanimously voted that the company,s second-generation female condom, ... , , The Advisory ... condition that the FC2 Female Condom,s instructions for use continue ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
... Case Medical Center in conjunction with Sodexo Health Care Services ... 24/6 unit, the original certified kosher hot food vending machine. ... in the state of Ohio, offering patients and their caregivers ... , University Hospitals prides itself ...
Cached Medicine News:Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3
... has been designed specifically for the ... involved in ward rounds. It is ... dosages, and consultations that are requested ... Registrar during Ward round examinations and ...
... tracking and billing. This ... Handheld application, a complete ... CPT™ and ICD-9-CM codes ... Designed for any medical ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
Medicine Products: